Table 3.
Breast | colorectal | brain | melanoma | prostate | non-small cell lung | ovarian | thyroid | pancreatic | renal cell | |
---|---|---|---|---|---|---|---|---|---|---|
CCL2 | +1 | + | +6 | + | vl | nd | - | nd | + | nd |
CCR2 | nd | vl | +6 | nd | + | + | nd | nd | vl | nd |
CCL5 | +1,2 | nc | nd | + | + | + | nd | +9 | + | nd |
CCR5 | +3 | nc | +7 | + | nd | + | nd | nd | nd | nd |
CXCL1 | +4 | + | +6,7 | + | + | nd | + | nd | nd | + |
CXCR2 | nd | + | +7 | + | + | + | + | +10 | + | + |
CXCL12 | v11,4 | + | +7 | nd | + | nd | + | nd | + | + |
CXCR4 | +1,5 | + | +6 | + | + | + | + | +9 | + | + |
(-): reduced expression, (+): increased expression, nd: not determined, vl: very low or undetectable; nc: no change
invasive ductal carcinoma
estrogen receptor negative (ER negative)/progesterone receptor negative stage II breast cancer
infiltrating ductal carcinoma and infiltrating lobular carcinoma
ER negative breast cancer
invasive lobular carcinoma
glioblastoma
glioma,
astrocytoma
papillary thyroid carcinoma
medullary thyroid carcinoma